RGC · Nasdaq · CIK 0001829667

Regencell Bioscience Holdings Ltd

Regencell Bioscience Holdings Ltd’s most recent SEC filing in our snapshot is a Form 20-F filed on Oct 7, 2026. Its EDGAR record lists 2 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2026
—
Net income, FY2026
-$11.7M
Form 4 filings on record, past 12 months
2

Company overview

Legal name (as filed)
Regencell Bioscience Holdings Ltd
Ticker
RGC
SEC Central Index Key (CIK)
0001829667
Business address
HONG KONG
State or country of incorporation
Cayman Islands
Fiscal year ends
—
SEC filer category
Large accelerated filer
Position in SEC ticker list
#1354 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Regencell Bioscience Holdings Ltd’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
n/aFY2022n/aFY2023n/aFY2024n/aFY2025n/aFY2026
Net income
-$7.4MFY2022-$5.9MFY2023-$4.3MFY2024-$3.6MFY2025-$11.7MFY2026
RGC annual results
ItemFY2022
ended Jun 30, 2022		FY2023
ended Jun 30, 2023		FY2024
ended Jun 30, 2024		FY2025
ended Jun 30, 2025		FY2026
ended Jun 30, 2026
Revenue—————
Net income-$7.4M-$5.9M-$4.3M-$3.6M-$11.7M
Diluted EPS-$0.58-$1.19-$0.87-$0.72-$2.37
Total assets$18.0M$12.6M$8.4M$5.8M$14.7M
Cash and equivalents$6.4M$1.6M$3.0M$2.4M$14.2M

XBRL tags used: netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

RGC latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Oct 7, 202620-FANNUAL REPORT· period Jun 30, 2026Document · Index
May 22, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period May 22, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about Regencell Bioscience Holdings Ltd, by form type:

6-K ×223 ×720-F ×44 ×2424B5 ×2SCHEDULE 13D/A ×2F-3ASR ×1
RGC recent filings
FiledFormWhat it isOriginal
Oct 7, 202620-FANNUAL REPORT· period Jun 30, 2026Document · Index
May 29, 20264Statement of changes in beneficial ownership (insider trade)· period May 27, 2026Document · Index
May 29, 20264Statement of changes in beneficial ownership (insider trade)· period May 27, 2026Document · Index
May 22, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period May 22, 2026Document · Index
May 19, 2026424B5PROSPECTUS SUPPLEMENTDocument · Index
May 19, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period May 19, 2026Document · Index
May 19, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period May 19, 2026Document · Index
May 8, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period Dec 31, 2025Document · Index
Apr 17, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period Apr 17, 2026Document · Index
Mar 30, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period Mar 30, 2026Document · Index
Mar 30, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period Mar 30, 2026Document · Index
Mar 30, 2026424B5PROSPECTUS SUPPLEMENTDocument · Index
Mar 30, 2026F-3ASRREGISTRATION STATEMENTDocument · Index
Mar 18, 20263Initial statement of beneficial ownership· period Mar 18, 2026Document · Index
Mar 18, 20263Initial statement of beneficial ownership· period Mar 18, 2026Document · Index
Mar 18, 20263Initial statement of beneficial ownership· period Mar 18, 2026Document · Index
Mar 18, 20263Initial statement of beneficial ownership· period Mar 18, 2026Document · Index
Mar 18, 20263Initial statement of beneficial ownership· period Mar 18, 2026Document · Index
Mar 18, 20263Initial statement of beneficial ownership· period Mar 18, 2026Document · Index
Mar 18, 20263Initial statement of beneficial ownership· period Mar 18, 2026Document · Index
Feb 13, 20266-KREPORT OF FOREIGN PRIVATE ISSUER· period Feb 13, 2026Document · Index
Oct 31, 202520-FANNUAL REPORT· period Jun 30, 2025Document · Index
Jul 11, 2025SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
Jun 30, 20256-KREPORT OF FOREIGN PRIVATE ISSUER· period Jun 30, 2025Document · Index
Jun 30, 20256-KREPORT OF FOREIGN PRIVATE ISSUER· period Jun 30, 2025Document · Index
Jun 17, 20256-KREPORT OF FOREIGN PRIVATE ISSUER· period Jun 17, 2025Document · Index
Jun 2, 20256-KREPORT OF FOREIGN PRIVATE ISSUER· period Jun 2, 2025Document · Index
Mar 13, 2025SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
Jan 15, 20256-KREPORT OF FOREIGN PRIVATE ISSUER· period Jan 15, 2025Document · Index
Oct 25, 202420-FANNUAL REPORT· period Jun 30, 2024Document · Index
Jun 20, 20246-KREPORT OF FOREIGN PRIVATE ISSUER· period Jun 20, 2024Document · Index
Jan 2, 20246-KREPORT OF FOREIGN PRIVATE ISSUER· period Jan 2, 2024Document · Index
Dec 15, 20236-KREPORT OF FOREIGN PRIVATE ISSUER· period Dec 15, 2023Document · Index
Oct 27, 202320-FANNUAL REPORT· period Jun 30, 2023Document · Index
Jun 15, 20236-KREPORT OF FOREIGN PRIVATE ISSUER· period Jun 15, 2023Document · Index
Jun 5, 20236-KREPORT OF FOREIGN PRIVATE ISSUER· period Jun 5, 2023Document · Index
Mar 17, 20236-KREPORT OF FOREIGN PRIVATE ISSUER· period Mar 17, 2023Document · Index
Feb 28, 20236-KREPORT OF FOREIGN PRIVATE ISSUER· period Feb 28, 2023Document · Index
Jan 4, 20236-KREPORT OF FOREIGN PRIVATE ISSUER· period Jan 4, 2023Document · Index
Dec 22, 20226-KREPORT OF FOREIGN PRIVATE ISSUER· period Dec 22, 2022Document · Index

Insider filing activity

2 Form 4 filings appear in Regencell Bioscience Holdings Ltd’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Medicinal Chemicals & Botanical Products

All 6 companies in Medicinal Chemicals & Botanical Products

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001829667 and XBRL company facts. Regencell Bioscience Holdings Ltd on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.